diagnost anim health
develop market life scienc tool
integr system analyz nucleic acid
creat develop market life
scienc tool integr system analyz
requir disclosur end report
pipelin novaseq drive upsid reiter buy rais
price
view current cl king meet event calendar coverag univers
calendar
consist pre-announce post excel quarter
beat top bottom line initi guidanc
expect thesi compani five year
unobstruct growth production-scal sequenc investor
underappreci abil scale sb chemistri think novaseq shore
weak near term reiter buy rate rais
price target
base case thesi platform compani via genom
sequenc data gener overal market backdrop grow doubl
digit clinic sequenc repres potenti growth acceler
consum growth stori double-digit growth re-fleet hiseq
novaseq four-year pace adopt base case
upsid case thesi order stock see signific upsid
valuat novaseq instrument need stage adopt
hiseq custom site find addit new high
thesi near term think situat fall somewher
scenario long-term opportun top platform
sequenc help maintain premium multipl view
quarter
novaseq pipelin hiseq/x custom adopt
novaseq mean upgrad cycl opportun remain place
think number jump good chunk
remain stage adopt whether negoti
look fund alloc novaseq-specif project
servic provid intern expect stagger
transit custom
novaseq current custom expect hiseq custom
least one novaseq ultra-high throughput chip
launch maintain new high throughput novaseq
order ratio one-third expect track howev
maintain ratio would repres upsid stock
benchtop sequenc although desktop sequenc repres
revenu repres much opportun clinic
new-to-sequenc custom nipt drive signific placement
nextseq new sequenc custom repres miniseq
miseq shipment low throughput custom mani case repres
potenti burgeon demand futur high throughput machin
report revenu vs
beat our/th street respect estim
non-gaap ep beat our/street expect
guidanc consist pre-announce three week ago
expect revenu expect
adjust ep ep adjust ep
miss estim beat street respect
benefit tax reform off-set helix dilut
model increas revenu estim
keep revenu estim essenti intact
lower adjust ep estim
reflect guidanc helix spend
rais adjust ep
iseq happi launch iseq think testament
incred engin think iseq chemistri
becom infrastructur high throughput instrument
key factor iseq remov expens optic
platform massiv room lower sequenc cost
valuat deriv price target use
multipl ep estim although
premium stock diagnost space believ
three five year unobstruct growth multibillion-dollar
address market multipl high end trade
histori howev visibl growth barrier new entranc
never higher
risk achiev price target
increas competit space
inabl protect proprietari technolog
adopt speed novaseq
decreas govern spend
chang fda rule
page
